Panitumumab vs Bevacizumab Added to Standard First-line Chem

This randomized clinical trial assesses the effect of adding panitumumab vs bevacizumab to standard first-line chemotherapy on overall survival among patients w

Related Keywords

Japan , Soeda , Fukuoka , Illinois , United States , Misumi , Kumamoto , Helsinki , Eteläuomen Läi , Finland , Makiyama , Yokohama , Kanagawa , Chicago , Nojima , Kagoshima , Shihara , Niigata , Ohori , Yamagata , Shitara , Aichi , Shiozawa , Japanese , Nippon , American , Solasia Pharma , Marko Rehn , Takayuki Yoshino , Merck Serono , Lela Creutz , Yakult Honsha , Merck Biopharma , Yukiko Sakakibara , Bayer Yakuhin , Kaken Pharma , Lauren Gallagher , Michelle Mcdermott , Eli Lilly , Asahi Kasei , Monte Carlo , Kazumi Nomura , Boehringer Ingelheim , Daiichi Sankyo , Or Foundation , Parexel International , Glaxosmithkline , National Cancer Center Hospital , Tsumura Co , Japan Clinical Oncology Group , Johnson , Guardant Health Japan , Genomedia Inc , Bristol Myers Squibb , Medtronic , Pfizer , Takeda Pharmaceutical Company , Eastern Cooperative Oncology Group , Hutchison Medipharma Incyte Corporation , Astrazeneca , Amgen , Institute Inc , Sysmex Corp , Peloton Advantage , Department Of Gastroenterology , Linical Co Ltd , Novartis , Japan Ministry Of Health , American Society Of Clinical Oncology Annual Meeting , Yokohama City University School Of Medicine , Clinical Research Act No , Pfizer Inc , Phd Amgen Inc , Merck Kgaa , Abbvie Inc , Department Of Biostatistics , Merck Kga , Takeda Pharmaceuticals , Certified Review Board , National Cancer Center Hospital East , Japan Registry , Clinical Trials , Clinical Research Act , International Council , Technical Requirements , Human Use , Good Clinical Practice , Response Evaluation Criteria , Solid Tumors , Common Terminology Criteria , Adverse Events , Size Calculation , Tripartite Guideline , Statistical Principles , Overall Survival , Free Survival , Participants With Right Sided Tumors , Post Hoc Outcomes , Gastrointestinal Oncology , Drs Watanabe , Interest Disclosures , Ono Pharmaceutical , Chugai Pharmaceutical , Merck Sharp , Taiho Pharmaceutical , Merck Pharmaceutical , Medi Science , Isofol Medical , Hutchison Medipharma , Incyte Corporation , Eli Lilly Japan , Sumitomo Bake , Nippon Zoki , Pfizer Japan , Nippon Boehringer Ingelheim , Yokohama City University School , American Society , Clinical Oncology Annual Meeting , Sharing Statement , Takeda Pharmaceutical Company Limited , Amgen Inc ,